Zhou Jian, Zhou Liang, Tao Lei, Zhang Ming, Wu Haitao, Chen Xiaoling, Li Xiaoming, Li Cai, Gong Hongli
a Department of Otorhinolaryngology , Fudan University, Eye Ear Nose and Throat Hospital , Shanghai , China.
b Department of Otolaryngology , Fudan University, Eye, Ear, Nose and Throat Hospital , Shanghai , China.
Acta Otolaryngol. 2018 Nov;138(11):1028-1034. doi: 10.1080/00016489.2018.1490031. Epub 2019 Feb 8.
T3 supraglottic laryngeal carcinoma (LC) is a common advanced laryngeal cancer.
This study was conducted to assess the clinical results of pathological T3 (pT3) supraglottic LC patients who were amenable to laryngectomy treated with primary surgery and postoperative therapy.
Retrospective review of 202 pT3 cases of supraglottic laryngeal squamous cell carcinoma.
The five-year cancer specific survival (CSS) rate was 63.7% and the overall survival rate (OS) was 62.8%. For T3 supraglottic patients who underwent total laryngectomy, the five-year disease-free survival (DFS) was 51.8%, and the CSS was 62.5%. For patients who underwent partial laryngectomy, the five-year DFS was 72.2%, and the CSS was 79.0%. High lymph node and stage status are predictors of mortality for these patients. No difference was found in the DFS and CSS rates between patients with negative margins and those with positive margins following postoperative radiotherapy and chemotherapy.
Surgical treatment of T3 supraglottic LC patients achieved satisfactory results. Postoperative radiotherapy and chemotherapy are an effective method of treatment for T3 supraglottic LC patients, especially for those with a positive margin.
T3 声门上型喉癌（LC）是一种常见的晚期喉癌。
本研究旨在评估适合行喉切除术的病理 T3（pT3）声门上型 LC 患者接受一期手术及术后治疗的临床效果。
回顾性分析 202 例声门上型喉鳞状细胞癌 pT3 病例。
五年癌症特异性生存率（CSS）为 63.7%，总生存率（OS）为 62.8%。对于接受全喉切除术的 T3 声门上型患者，五年无病生存率（DFS）为 51.8%，CSS 为 62.5%。对于接受部分喉切除术的患者，五年 DFS 为 72.2%，CSS 为 79.0%。高淋巴结转移及分期是这些患者死亡的预测因素。术后放疗和化疗后，切缘阴性和阳性患者的 DFS 及 CSS 率无差异。
T3 声门上型 LC 患者的手术治疗取得了满意的效果。术后放疗和化疗是 T3 声门上型 LC 患者，尤其是切缘阳性患者的有效治疗方法。
